Unigen Pharmaceuticals has added to its portfolio of patented products and processes with the award of a US patent for a new process called MaxCell, created by Unigen's vice president of scientific affairs Qi Jia.
The MaxCell process can be used for the delivery of a variety of biologically active agents, according to Unigen.
"MaxCell can be used to deliver a variety of biologically active agents including, but not limited to, nutrients and dietary supplements such as essential minerals, vitamins, amino acids and derivatives, hormones and formulas," said Jia.
"We have worked hard at establishing a dominant patent estate and are very pleased with the results so far."
The components of MaxCell not only function as a classical delivery system to target bioavailability but also emphasise the response from the targeted living cells through renewal, enhancement and protection functions, Jia continued.
Unigen focuses on the research and development of botanically derived therapeutic compounds, including identifying and studying the unique ingredients of medicinal botanicals and then formulating proprietary raw materials for use in cosmeceutical, nutraceutical and pharmaceutical products.